Allervi

Allervi is an over‑the‑counter oral medication that contains the antihistamine fexofenadine hydrochloride. Marketed in the European Union as tablets (strength not specified), it is a second‑generation H1‑receptor antagonist that acts peripherally to reduce histamine‑mediated symptoms without causing significant sedation. Allervi is intended for self‑medication of allergic rhinitis and chronic idiopathic urticaria in adults. It is suitable for use during the allergy season and is generally well tolerated.

Allervi is indicated for the temporary relief of symptoms associated with allergic conditions.

- Seasonal allergic rhinitis (hay fever) symptoms such as sneezing, nasal discharge, and itchy nose. - Perennial allergic rhinitis symptoms caused by year‑round allergens. - Chronic idiopathic urticaria (hives) presenting with itchy, raised welts. - Relief of eye itching and watering due to allergic conjunctivitis. - Adjunctive use for mild to moderate allergy symptoms when non‑pharmacologic measures are insufficient. - Management of intermittent allergy flare‑ups in adults who prefer an oral, non‑sedating option.

The safety profile of Allervi reflects the typical experience with second‑generation antihistamines.

Common: - Headache, which is usually mild and transient. - Dry mouth or mild throat dryness. - Mild gastrointestinal discomfort such as nausea, abdominal pain, or dyspepsia. - Drowsiness, which occurs less frequently than with first‑generation antihistamines. - Fatigue or a feeling of reduced energy. - Insomnia or difficulty falling asleep. - Altered taste sensation.

Serious: - Severe allergic reaction (anaphylaxis) with symptoms such as swelling, rash, or difficulty breathing. - Cardiac arrhythmia or prolonged QT interval, reported very rarely. - Significant liver enzyme elevation indicating possible hepatic involvement (rare).

Most users experience only mild, transient effects, while serious reactions are uncommon.

When considering Allervi, certain precautions and warnings should be observed to ensure safe use.

- Consult a healthcare professional before use if you have known liver or kidney impairment. - Use caution in patients with a history of cardiac disease, especially those prone to arrhythmias. - Do not exceed the recommended daily dose; higher doses have not been shown to improve efficacy. - Pregnant or breastfeeding women should seek medical advice before taking Allervi. - Avoid driving or operating machinery until you know how Allervi affects you, as rare drowsiness may occur. - Keep out of reach of children; accidental ingestion can cause adverse effects.

Allervi may interact with other medicines or substances; awareness of these interactions helps maintain effectiveness and safety.

Avoid: - Avoid concomitant use with ketoconazole or erythromycin, which can increase fexofenadine plasma concentrations. - Avoid taking Allervi with antacids containing aluminum or magnesium within 15 minutes before or after the dose, as absorption may be reduced.

Use with caution: - Use with caution when combined with other antihistamines or sedating medications, as additive effects on drowsiness can occur. - Use with caution in patients taking medications that prolong the QT interval; monitor cardiac status if necessary. - Use with caution in individuals on strong CYP3A4 inhibitors, although fexofenadine is minimally metabolized, monitoring is advisable.